Skip to main content
. 2022 Jan 5;42(1):2–15. doi: 10.1523/JNEUROSCI.1132-21.2021

Figure 3.

Figure 3.

Loss of AnkR results in ataxia and abnormal gait. Quantification of footprints from gait analysis at (A) one-month-old control (N = 10; stride 5.9 ± 0.17 cm; stance 3.8 ± 0.10 cm; sway 2.3 ± 0.06 cm); Ank1F/F;Nestin-Cre (N = 10; stride 3.8 ± 0.16 cm; stance 3.2 ± 0.06 cm; sway 2.6 ± 0.06 cm); and Ank1F/F;Pcp2-Cre (N = 7; stride 4.9 ± 0.17 cm; stance 3.8 ± 0.09 cm; sway 2.7 ± 0.07 cm); (B) six-month-old control (N = 10; stride 6.9 ± 0.18 cm; stance 4.5 ± 0.10 cm; sway 2.5 ± 0.04 cm); Ank1F/F;Nestin-Cre (N = 9; stride 4.5 ± 0.29 cm; stance 3.8 ± 0.19 cm; sway 3.0 ± 0.11 cm); and Ank1F/F;Pcp2-Cre (N = 7; stride 5.0 ± 0.14 cm; stance 3.8 ± 0.10 cm; sway 2.9 ± 0.08 cm); and (C) 12-month-old control (N = 10; stride 6.5 ± 0.18 cm; stance 4.5 ± 0.10 cm; sway 2.7 ± 0.10 cm); Ank1F/F;Nestin-Cre (N = 8; stride 3.4 ± 0.22 cm; stance 3.7 ± 0.18 cm; sway 3.3 ± 0.12 cm); and Ank1F/F;Pcp2-Cre (N = 7; stride 4.3 ± 0.17 cm; stance 3.7 ± 0.07 cm; sway 3.2 ± 0.06 cm). Error bars indicate mean ± SEM. D, Sample footprints from six-month-old control, Ank1F/F;Nestin-Cre, and Ank1F/F;Pcp2-Cre mice, measurements used for analysis depicted in gray.